Active substance
Results for the substance enfortumab vedotin
4 results
About this active substance
Enfortumab vedotin is a medication used to treat certain advanced forms of bladder cancer. It is an antibody-drug conjugate that targets cancer cells specifically, delivering a cytotoxic agent to destroy them and limit the spread of the disease. Enfortumab vedotin is recommended for patients who have not responded to other therapies or immunotherapy.
The medication is administered by intravenous infusion in a hospital setting, under the supervision of a specialized medical team. The treatment schedule and dose are determined by the doctor based on the patient's general condition and response to therapy.
Side effects may include fatigue, nausea, hair loss, skin rashes, peripheral neuropathy, or infections. Rarely, severe reactions such as liver damage or serious allergic responses may occur. Careful monitoring is essential throughout the treatment.
Enfortumab vedotin provides a modern therapeutic option for patients with advanced bladder cancer, but its use requires strict medical supervision to effectively manage possible side effects.
The medication is administered by intravenous infusion in a hospital setting, under the supervision of a specialized medical team. The treatment schedule and dose are determined by the doctor based on the patient's general condition and response to therapy.
Side effects may include fatigue, nausea, hair loss, skin rashes, peripheral neuropathy, or infections. Rarely, severe reactions such as liver damage or serious allergic responses may occur. Careful monitoring is essential throughout the treatment.
Enfortumab vedotin provides a modern therapeutic option for patients with advanced bladder cancer, but its use requires strict medical supervision to effectively manage possible side effects.